Press release
Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc., Akcea Therapeutics
Download the sample report @ https://www.pharmaproff.com/request-sample/1077
Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy.
Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis
The symptoms associated with the disease includes loss of body fat, diabetes, deposition of fat, high triglyceride level and fatty liver. Lipodystrophy can be treated by medications, hormone treatments, cosmetic implants, and surgery.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1077
Ionis Pharmaceuticals Inc. is in the process of developing Volanesorsen in partnership with Akcea Therapeutics for the treatment of familial partial lipodystrophy.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc., Akcea Therapeutics here
News-ID: 1759124 • Views: …
More Releases for Ionis
Transthyretin Amyloid Cardiomyopathy Treatment Market Deep Research Report - Pfi …
Transthyretin Amyloid Cardiomyopathy Treatment Market Insights
Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at USD 2.91 Bn in 2025 and is expected to reach USD 19.37 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 31.1% from 2025 to 2032.
Coherent Market Insights has published a new comprehensive analysis on the Transthyretin Amyloid Cardiomyopathy Treatment Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This…
Gene Silencing Market Hits New High | Major Giants Alnylam, Silence Therapeutics …
HTF MI just released the Global Gene Silencing Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Gene Silencing Market are: Alnylam, Silence Therapeutics,…
Angelman Syndrome Market Is Booming Worldwide 2025-2032 | Roche Biogen,Ionis Pha …
According to the latest research from Coherent Market Insights, the Angelman Syndrome Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough research, highlighting current trends, financial performance, and historical data evaluation. The company profiles within the report are derived from the current performance of the Angelman Syndrome Market, considering key factors such as drivers, trends, and challenges, as…
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsi …
The Key Multiple System Atrophy Companies in the marlet include - Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
DelveInsight's "Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Multiple System Atrophy, historical and…
Nucleic Acid Therapy Market Touching New Development Level |Alnylam, Ionis Pharm …
According to HTF Market Intelligence, the Global Nucleic Acid Therapy market to witness a CAGR of 11.6% during the forecast period (2024-2030). The Latest Released Nucleic Acid Therapy Market Research assesses the future growth potential of the Nucleic Acid Therapy market and provides information and useful statistics on market structure and size.
This report aims to provide market intelligence and strategic insights to help decision-makers make sound investment decisions and…
Familial Chylomicronemia Syndrome Market to Exhibit Substantial Growth Rate Duri …
As per DelveInsight, the Familial Chylomicronemia Syndrome Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Familial Chylomicronemia Syndrome and the launch of new therapies in the market.
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Chylomicronemia Syndrome market…
